Table 2. Resistant clones harboring a BCR-ABL1-KD mutation.
Exp. | TKI | UT-7 cell line | MS-5 feeder | Clones tested for mutation | Results of mutation analysis | |||
---|---|---|---|---|---|---|---|---|
Number | Available** | No mutation | one mutation | two mutations | ||||
1 | imatinib | UT-7-11 | − | 24 | 22 | 2 | 20 | 0 |
+ | 24 | 23 | 0 | 23 | 0 | |||
2 | nilotinib | UT-7-11 | − | 24 | 24 | 11 | 12 | 1 |
+ | 24* | 24 | 13 | 11 | 0 | |||
3 | dasatinib | UT-7-11 | − | 12 | 12 | 1 | 11 | 0 |
+ | 11 | 11 | 1 | 10 | 0 | |||
4 | ponatinib | UT-7-315 | − | 48 | 47 | 0 | 10*** | 37**** |
+ | 48 | 46 | 0 | 34*** | 12**** | |||
5 | ponatinib | UT-7-11 | − | 0 | 0 | 0 | 0 | 0 |
+ | 24 | 24 | 0 | 22*** | 2**** |
Methylcellulose colonies after 14 days of culture in the presence of nilotinib.
Clones correctly expanded in 24-well plates.
T315I mutation alone.
one mutation in addition to the T315I mutation.